1. Cabrera, CS, Nan, C, Lindarck, N, et al SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting beta2-agonist use in asthma. Eur Respir J 2019; 55: 1901858.
Google Scholar | Crossref2. O’Byrne, PM, Jenkins, C, Bateman, ED. The paradoxes of asthma management: time for a new approach? Eur Respir J 2017; 50: 1701103.
Google Scholar | Crossref | Medline3. Reddel, HK, FitzGerald, JM, Bateman, ED, et al GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019; 53: 1901046.
Google Scholar | Crossref | Medline4. Beasley, R, Bird, G, Harper, J, et al The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J 2018; 52: 1800694.
Google Scholar | Crossref | Medline5. Patel, M, Pilcher, J, Pritchard, A, et al Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32–42.
Google Scholar | Crossref | Medline6. Royal College of Physicians . Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report, https://www.asthma.org.uk/293597ee/globalassets/campaigns/nrad-full-report.pdf (2014, accessed 18 March 2020).
Google Scholar7. Global Initiative for Asthma. 2019 GINA report, global strategy for asthma management and prevention, https://ginasthma.org/gina-reports/ (2019, accessed 9 July 2019).
Google Scholar8. Global Initiative for Asthma . Global strategy for asthma management and prevention, https://ginasthma.org (2020, accessed 12 May 2020).
Google Scholar9. Janson, C, Menzies-Gow, A, Nan, C, et al SABINA: an overview of short-acting beta2-agonist use in asthma in European countries. Adv Ther 2020; 37: 1124–1135.
Google Scholar | Crossref | Medline10. Hong, SH, Sanders, BH, West, D. Inappropriate use of inhaled short acting beta-agonists and its association with patient health status. Curr Med Res Opin 2006; 22: 33–40.
Google Scholar | Crossref | Medline11. Wolfenden, LL, Diette, GB, Skinner, EA, et al Gaps in asthma care of the oldest adults. J Am Geriatr Soc 2002; 50: 877–883.
Google Scholar | Crossref | Medline12. Bonner, S, Matte, T, Rubin, M, et al Oral beta2-agonist use by preschool children with asthma in East and Central Harlem, New York. J Asthma 2006; 43: 31–35.
Google Scholar | Crossref | Medline | ISI13. Barthwal, MS, Deoskar, RB, Rajan, KE. Status of inhalation therapy in bronchial asthma in adults above twelve years of age in armed forces. J Assoc Physicians India 2005; 53: 681–684.
Google Scholar | Medline14. Belhassen, M, Nibber, A, Van Ganse, E, et al Inappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study. NPJ Prim Care Respir Med 2016; 26: 16076.
Google Scholar | Crossref | Medline15. Gildon, BL, John, B, Condren, M, et al Pharmacist-managed short-acting beta agonist refill service in a general pediatric clinic. J Am Pharm Assoc (2003) 2018; 58: 296–302.
Google Scholar | Crossref | Medline16. Sa-Sousa, A, Almeida, R, Vicente, R, et al High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis. Clin Transl Allergy 2019; 9: 47.
Google Scholar | Crossref | Medline17. Azzi, EA, Kritikos, V, Peters, MJ, et al Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open 2019; 9: e028995.
Google Scholar | Crossref | Medline18. Janson, SL, Earnest, G, Wong, KP, et al Predictors of asthma medication nonadherence. Heart Lung 2008; 37: 211–218.
Google Scholar | Crossref | Medline19. Nwaru, BI, Ekstrom, M, Hasvold, P, et al Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55: 1901872.
Google Scholar | Crossref | Medline20. Vervloet, M, van Dijk, L, Spreeuwenberg, P, et al The relationship between real-world inhaled corticosteroid adherence and asthma outcomes: a multilevel approach. J Allergy Clin Immunol Pract 2019; 8: 626–634.
Google Scholar | Crossref | Medline21. O’Byrne, P, FitzGerald, J, Bateman, E, et al Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med 2018; 378: 1865–1876.
Google Scholar | Crossref | Medline22. Patel, M, Pilcher, J, Reddel, HK, et al Predictors of severe exacerbations, poor asthma control, and beta-agonist overuse for patients with asthma. J Allergy Clin Immunol Pract 2014; 2: 751–758.
Google Scholar | Crossref | Medline23. Patel, M, Pilcher, J, Reddel, HK, et al Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy 2013; 43: 1144–1151.
Google Scholar | Medline24. Perry, TT, Rettiganti, M, Brown, RH, et al Uncontrolled asthma and factors related to morbidity in an impoverished, rural environment. Ann Allergy Asthma Immunol 2012; 108: 254–259.
Google Scholar | Crossref | Medline25. Suissa, S, Ernst, P, Boivin, JF, et al A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.
Google Scholar | Crossref | Medline | ISI26. Slejko, JF, Ghushchyan, VH, Sucher, B, et al Asthma control in the United States, 2008-2010: indicators of poor asthma control. J Allergy Clin Immunol 2014; 133: 1579–1587.
Google Scholar | Crossref | Medline | ISI27. Papi, A, Canonica, GW, Maestrelli, P, et al Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356: 2040–2052.
Google Scholar | Crossref | Medline | ISI28. Beasley, R, Holliday, M, Reddel, HK, et al Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380: 2020–2030.
Google Scholar | Crossref | Medline29. Bateman, ED, Reddel, HK, O’Byrne, P, et al As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378: 1877–1887.
Google Scholar | Crossref | Medline30. Hardy, J, Baggott, C, Fingleton, J, et al Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019; 394: 919–928.
Google Scholar | Crossref | Medline31. Rabe, KF, Pizzichini, E, Stallberg, B, et al Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246–256.
Google Scholar | Crossref | Medline32. Scicchitano, R, Aalbers, R, Ukena, D, et al Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403–1418.
Google Scholar | Crossref | Medline33. O’Byrne, PM, Bisgaard, H, Godard, PP, et al Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129–136.
Google Scholar | Crossref | Medline | ISI34. Rabe, KF, Atienza, T, Magyar, P, et al Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744–753.
Google Scholar | Crossref | Medline | ISI35. Kuna, P, Peters, MJ, Manjra, AI, et al Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725–736.
Google Scholar | Crossref | Medline | ISI36. Bousquet, J, Boulet, LP, Peters, MJ, et al Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437–2446.
Google Scholar | Crossref | Medline37. Bateman, ED, Reddel, HK, Eriksson, G, et al Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600–8608.
Google Scholar | Crossref | Medline | ISI38. Papi, A, Corradi, M, Pigeon-Francisco, C, et al Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 23–31.
Google Scholar | Crossref | Medline39. Boonsawat, W, Thinkhamrop, B. Role of budesonide/formoterol maintenance and reliever therapy: a pragmatic study. Asian Pac J Allergy Immunol 2014; 32: 160–165.
Google Scholar | Medline40. Kim, SH, Kim, TB, Kim, SH, et al Real-life clinical use of Symbicort® maintenance and reliever therapy for asthmatic patients in Korea. Allergy Asthma Immunol Res 2018; 10: 88–94.
Google Scholar | Crossref | Medline41. Sobieraj, DM, Weeda, ER, Nguyen, E, et al Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319: 1485–1496.
Google Scholar | Crossref | Medline42. Global Initiative for Asthma . Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management, https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf (2019, accessed 23 March 2020).
Google Scholar43. Beasley, R, Braithwaite, I, Semprini, A, et al ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J 2020; 55: 1901407.
Google Scholar | Crossref | Medline